GSK (NYSE:GSK) Rating Increased to Strong-Buy at StockNews.com

GSK (NYSE:GSK) was upgraded by equities research analysts at StockNews.com from a “buy” rating to a “strong-buy” rating in a research report issued on Thursday.

A number of other analysts have also recently issued reports on the stock. Deutsche Bank Aktiengesellschaft cut shares of GSK from a “buy” rating to a “hold” rating in a research note on Friday, November 15th. Jefferies Financial Group cut GSK from a “buy” rating to a “hold” rating and decreased their price target for the company from $53.00 to $39.50 in a report on Tuesday, November 12th. Barclays raised GSK to a “hold” rating in a research note on Tuesday, August 27th. Finally, Guggenheim downgraded GSK from a “buy” rating to a “neutral” rating in a research note on Thursday, October 31st. Seven investment analysts have rated the stock with a hold rating and four have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, GSK currently has an average rating of “Moderate Buy” and an average target price of $43.25.

GSK Trading Down 0.7 %

Shares of NYSE:GSK opened at $33.95 on Thursday. The stock has a 50 day moving average of $36.28 and a 200 day moving average of $39.36. The company has a market cap of $70.35 billion, a PE ratio of 22.19, a price-to-earnings-growth ratio of 1.54 and a beta of 0.64. GSK has a 12-month low of $32.83 and a 12-month high of $45.92. The company has a current ratio of 0.81, a quick ratio of 0.53 and a debt-to-equity ratio of 0.98.

Insiders Place Their Bets

In other GSK news, major shareholder Plc Gsk acquired 2,791,930 shares of the company’s stock in a transaction on Friday, September 27th. The stock was acquired at an average cost of $8.00 per share, with a total value of $22,335,440.00. Following the purchase, the insider now directly owns 16,775,691 shares of the company’s stock, valued at approximately $134,205,528. This represents a 19.97 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 10.00% of the company’s stock.

Institutional Trading of GSK

Hedge funds have recently made changes to their positions in the business. Sunbelt Securities Inc. grew its position in GSK by 73.8% in the third quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company’s stock worth $29,000 after acquiring an additional 302 shares in the last quarter. EverSource Wealth Advisors LLC lifted its stake in shares of GSK by 9.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 3,542 shares of the pharmaceutical company’s stock valued at $137,000 after purchasing an additional 303 shares during the last quarter. Mesirow Financial Investment Management Inc. boosted its holdings in shares of GSK by 2.0% in the 3rd quarter. Mesirow Financial Investment Management Inc. now owns 16,693 shares of the pharmaceutical company’s stock worth $682,000 after purchasing an additional 323 shares during the period. International Assets Investment Management LLC increased its position in shares of GSK by 6.3% during the 2nd quarter. International Assets Investment Management LLC now owns 5,535 shares of the pharmaceutical company’s stock valued at $213,000 after purchasing an additional 327 shares during the last quarter. Finally, Rehmann Capital Advisory Group raised its holdings in GSK by 6.3% during the 3rd quarter. Rehmann Capital Advisory Group now owns 5,608 shares of the pharmaceutical company’s stock valued at $232,000 after buying an additional 332 shares during the period. 15.74% of the stock is currently owned by hedge funds and other institutional investors.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.